Practical management of patients on apixaban: A consensus guide

Thrombosis Journal

Volumn 11, Issue 1, 2013, Pages

  Ward, Christopher ^a   Conner, Greg ^b   Donnan, Geoffrey ^c   Gallus, Alexander ^d   McRae, Simon ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Cardiovascular Diagnostic Services   (Australia)

^c AUSTIN HOSPITAL   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Apixaban; Bleeding; Novel oral anticoagulants; Perioperative management

Indexed keywords

APIXABAN; LOW MOLECULAR WEIGHT HEPARIN; PRT 064445; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ANESTHESIA; AUSTRALIA; BLEEDING; CEREBROVASCULAR ACCIDENT; EMERGENCY TREATMENT; HEALTH CARE PERSONNEL; HEART ATRIUM FIBRILLATION; HUMAN; MORTALITY; PRESCRIPTION; REVIEW;

EID: 84891367149     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-11-27     Document Type: Review

References (29)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, the RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-5. 10.1056/NEJMoa0905561, 19717844, the RE-LY Steering Committee and Investigators.
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, and the ROCKET AF Steering Committee, for the ROCKET AF Investigator Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891. 10.1056/NEJMoa1009638, 21830957, and the ROCKET AF Steering Committee, for the ROCKET AF Investigator.
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, et al. ARISTOTLE Committees and Investigators: apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011, 365:981-992. 10.1056/NEJMoa1107039, 21870978.
4. Frost C, Nepal S, Wang J, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, Lacreta F. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013, 75(2):476-487. 10.1111/j.1365-2125.2012.04369.x, 3558798, 22759198.
5. ELIQUIS® (Apixaban) Approved Product Information 2013, Bristol-Myers Squibb Australia Pty Ltd and Pfizer Pty Ltd, http://www.bmsa.com.au/products/pages/Home.aspx.
6. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim K-H, Lewis BS, Van Mieghem W, Lip GYH, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817. 10.1056/NEJMoa1007432, 21309657.
7. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365:699-708. 10.1056/NEJMoa1105819, 21780946.
8. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L, APPRAISE Steering Committee and Investigators Apixaban, an oral, direct, selective Factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome. Circulation 2009, 119:2877-2885. APPRAISE Steering Committee and Investigators.
9. Douxfils J, Chatelain C, Chatelain B, Dogné J-M, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013, 110(2):283-294. 10.1160/TH12-12-0898, 23765180.
10. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin LC, Alexander JH. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011, 32:183-187. 10.1007/s11239-011-0591-8, 21516308.
11. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010, 104:1263-1271. 10.1160/TH10-05-0328, 20978714.
12. Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 2012, 19(5):522-528.
13. Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, Lacreta F, Frost CE. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol: Advances and Applications 2013, 5:59-66.
14. Camm AJ, Lip GY, Caterina R, Savelieva I, Atar D, Hohnloser SH, G H, Kirchhof P, ESC Committee for Practice Guidelines (CPG) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012, 33:2719-2747. ESC Committee for Practice Guidelines (CPG).
15. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012, 33:2821-2830. 10.1093/eurheartj/ehs274, 22933567.
16. Granger CB, Alexander JH, Hanna M, Wang J, Mohan P, Lawrence J, Hylek E, Ansell JE, Wallentin L, for the ARISTOTLE investigators Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial [abstract]. Eur Heart J 2012, 33(Abstract Supplement):685-686. for the ARISTOTLE investigators.
17. Wang X, Tirucherai G, Pannacciulli, Wang J, Elsrougy A, Teslenko V, Chang M, Zhang D, Frost C. Effect of activated charcoal on the pharmacokinetics of apixaban in healthy subjects [abstract]. Clinical Pharmacol Ther 2012, 91(Suppl 1):s41.
18. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Uma S. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013, 19(4):446-451. 10.1038/nm.3102, 23455714.
19. Laulicht B, Bakhru S, Lee C, Baker C, Jiang X, Mathiowitz E, Costin J, Steiner S. Small molecule antidote for anticoagulants [abstract]. Circulation 2012, 126:A11395.
20. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579. 10.1161/CIRCULATIONAHA.111.029017, 21900088.
21. Escolar G, Arellano-Rodrigo E, Reverter JC, Villalta J, Sanz V, Molina P, Diaz-Ricart M, Galan AM. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood [abstract]. Circulation 2012, 126:520-521.
22. Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, Godier A. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 2013, 168:4228-4233. 10.1016/j.ijcard.2013.07.152, 23928345.
23. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, ORtel TL, Van Cott EM, Ansell J. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012, 87(Suppl 1):S141-S145.
24. Bauer KA. Reversal of antithrombotic agents. Am J Hematol 2012, 87(Suppl 1):S119-S126.
25. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012, 107:253-259.
26. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost 2012, 108:217-224. 10.1160/TH12-03-0179, 22627883.
27. Ferrandis R, Castillo J, de Andrés J, Gomar C, Gómez-Luque A, Hidalgo F, Llau JV, Sierra P, Torres LM. The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost 2013, 110:515-522. 10.1160/TH12-11-0868, 23846475.
28. Baron TH, Kamath PS, McBane RD. Antithrombotic therapy and invasive procedures. New Engl J Med 2013, 368:1079-1080.
29. Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des 2010, 16:3436-3441. 10.2174/138161210793563338, 20858185.